Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer

Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer

Abstract Background In the recent phase III trial MPACT the combination of gemcitabine and nab-paclitaxel (Gem/NabP) showed increased overall survival compared to gemcitabine alone in the treatment of advanced pancreatic ductal adenocarcinoma (aPDA). Until now there has been limited information on t...

Full description

Bibliographic Details
Main Authors: Hakon Blomstrand, Ursula Scheibling, Charlotte Bratthäll, Henrik Green, Nils O. Elander
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Cancer
Subjects:
Pancreatic cancer
Chemotherapy
Gemcitabine
Nab-paclitaxel
Bone marrow toxicity
Online Access:http://link.springer.com/article/10.1186/s12885-018-5244-2

Internet

http://link.springer.com/article/10.1186/s12885-018-5244-2

Similar Items